Navigation Links
Eurocine Vaccines Strengthens the Organization for Further Development
Date:4/7/2017

STOCKHOLM, April 7, 2017 /PRNewswire/ -- Eurocine Vaccines strengthens the organization with necessary competence, not only to prepare for further development of its first product, the nasal influenza vaccine candidate Immunose™ FLU, but also for further development of a pipeline of other vaccines based on the patented technology platform Endocine™.

"In parallel with finalizing the analyses and evaluation of the current study, we now prepare for the next steps of development. Reinforcing the organization with Sandra Jeldes Granstrand, a senior and experienced Project Leader of CMC[1], supports our ambitious strategy and rapid development ahead", said CSO Anna-Karin Maltais.

Simultaneously, CSO Anna-Karin Maltais is appointed Vice President Research and Development.

"This emphasizes our positive ambitions as we continue building value", said CEO Hans Arwidsson and continued "Ensuring that the next influenza season can be well used for further development, opens for a shorter way to market, to the benefit of patients and partners."

Results from the ongoing clinical study are expected in June/July 2017.

More information about the study can be found at www.clinicaltrials.gov.

[1] Chemistry Manufacturing and Control

CONTACT:
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com  
+46-70-634-0171

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/eurocine-vaccines/r/eurocine-vaccines-strengthens-the-organization-for-further-development,c2235009

The following files are available for download:

http://mb.cision.com/Main/11552/2235009/654837.pdf

Se news release

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eurocine-vaccines-strengthens-the-organization-for-further-development-300436536.html


'/>"/>
SOURCE Eurocine Vaccines
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Animal Vaccines Market Expected to Reach $9,159 Million by 2022 - Allied Market Research
2. New Access to Vaccines Index Reveals First Landscape of Vaccine Company Actions to Improve Immunisation Coverage
3. Immunomodulators Market Analysis By Product (Immunosuppressant, Immunostimulants, Vaccines, Antibodies), By Application (Oncology, Respiratory, HIV), By Region, And Segment Forecasts, 2014 - 2025
4. Global Influenza Vaccines - World Industry Market Outlook 2017-2027
5. Research and Markets - Global Travel Vaccines Market 2016-2020: Market Growth at CAGR of 6.83% - Growing Demand Among Travelers / Additional Age Group Approval / Inclusion in NIP
6. Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
7. Global Influenza Vaccines Market and Forecast to 2021: North America Accounted for 50% of the $5 Billion Market in 2015 - Research and Markets
8. Research and Markets - Global H1N1 Vaccines Market Analysis 2016-2025 - Trends, Technologies & Opportunities Report 2016-2025 - Vendors: Novartis, Zydus Cadila, Merck
9. Vaccines a 28 Billion-Dollar Market, Kalorama Information Study Finds
10. Kalorama: After Allergan Merger Halt, Vaccines a Focus for Pfizer
11. Profectus and Vyriad Form Global Collaboration to Develop Oncolytic Recombinant VSV (rVSV) Vaccines for Cancer Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... latest in wound care advancements to physician colleagues, skilled nursing facility medical directors ... "Navigating the Treacherous Waters of Wound Care." , "At many of these conferences ...
Breaking Medicine News(10 mins):